For adult patients with generalized myasthenia gravis (gMG) who are anti-AChR or anti-MuSK antibody positive

UPLIZNA® inebilizumab-cdon

DAY 1 ✓ | **UPLIZNA dose**

MONTH 6 ✓ | **Next UPLIZNA dose**

Twice-yearly* UPLIZNA,

PROVEN TO *HELP YOU* DO MORE

*Twice-yearly dosing begins after 2 startup infusions, given 2 weeks apart.

AChR, acetylcholine receptor; MuSK, muscle specific tyrosine kinase.

What is UPLIZNA® (inebilizumab-cdon)?

UPLIZNA is a prescription medicine used to treat adults with: Neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive; Immunoglobulin G4-related disease (IgG4-RD); Generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive. It is not known if UPLIZNA is safe or effective in children.

IMPORTANT SAFETY INFORMATION

Who should not receive UPLIZNA?

You should not receive UPLIZNA if you have:

- had a life-threatening infusion reaction to UPLIZNA.
- an active hepatitis B virus infection.
- active or untreated inactive (latent) tuberculosis.

Please see UPLIZNA full Prescribing Information, including Medication Guide.

gMG is a rare condition that occurs when the immune system targets the body's own tissues, resulting in muscle weakness and fatigue

In most patients, gMG is a lifelong disease that requires long-term treatment

Without effective treatment, gMG symptoms can return often and without warning—and may look different from one person to the next.

General fatigue is a common symptom, and other symptoms may include:

Eyes

- Eyelid drooping
- Blurred or double vision

Face, mouth, and throat

- Difficulty speaking
- Difficulty chewing and/or swallowing

Limbs

- Weakness in arms and hands
- Difficulty standing and walking

Breathing

- Difficulty breathing

gMG doesn't have to compromise your lifestyle

The goals for gMG treatment are to:

1. **Reduce gMG symptoms,** such as fatigue and muscle weakness
2. **Establish a long-term management plan** that works for your lifestyle



Please see UPLIZNA full Prescribing Information, including Medication Guide.

B cells* are a key driver of gMG disease activity

In a healthy immune system, B cells help fight infections like the common cold and flu.

In gMG they can sometimes make autoantibodies—a type of protein that attacks healthy parts of the body, such as the connection between the nerves and muscles. That's what can lead to symptoms like muscle weakness and fatigue.

There are 3 types of autoantibodies in gMG:



No matter the type of autoantibody, **gMG can have a major impact on a person's daily activities**. Symptoms can worsen over time and affect day-to-day life

*B cells are a type of white blood cell. They are part of the immune system that produces antibodies that target and destroy harmful viruses and bacteria.

AChR, acetylcholine receptor; LRP4, low-density lipoprotein receptor-related protein 4; MuSK, muscle specific tyrosine kinase.

UPLIZNA works differently by **targeting a key source of gMG**

UPLIZNA is the first and only FDA-approved anti-AChR or anti-MuSK antibody positive gMG treatment that targets and reduces harmful B cells

While the way UPLIZNA works in gMG is unknown, it is thought to target and reduce CD19 B cells. These B cells are believed to produce harmful autoantibodies that interfere with how nerves and muscles communicate.

Scan to learn how UPLIZNA works differently—by targeting a key source of gMG activity

Please see UPLIZNA full Prescribing Information, including Medication Guide.

UPLIZNA delivered gMG symptom improvement **with just two infusions per year***

UPLIZNA® inebilizumab-cdon

2x improvement in daily activities

In a 26-week study, patients taking UPLIZNA had a 4.2 point improvement in MG-ADL score vs a 2.2 point improvement for patients on placebo.[†,‡]

Just 2 infusions per year*

Safety profile backed by results from the largest study of adult patients with anti-AChR and anti-MuSK antibody positive gMG

The most common side effects were headache and infusion-related reaction.

*Twice-yearly dosing begins after 2 startup infusions, given 2 weeks apart.

[†]Placebo is a substance that has no therapeutic effect and is often used as a control in testing drugs.

[‡]Myasthenia Gravis Activities of Daily Living (MG-ADL) scale measures daily functions of 8 signs or symptoms that are typically affected in gMG.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about UPLIZNA?

UPLIZNA may cause serious side effects, including:

Infusion reactions. UPLIZNA can cause infusion reactions, including anaphylaxis, that can be serious or may cause you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of UPLIZNA for signs and symptoms of an infusion reaction. Tell your healthcare provider right away if you get any of these symptoms:

- headache
- nausea
- sleepiness
- shortness of breath
- fever
- muscle aches
- rash
- palpitations

If you develop an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion and treat your symptoms.

Please see UPLIZNA full Prescribing Information, including Medication Guide.

The MINT study was designed to represent the **real-world gMG patient population**

Study Design

UPLIZNA was evaluated in a **global study of 238 patients** from diverse backgrounds. The 26-week MINT study included adults with anti-AChR and anti-MuSK antibody positive gMG, and anti-AChR antibody positive patients remained in the study for 1 year.

The main goals of the study were to see how UPLIZNA:

Improved daily activities (based on MG-ADL scale)

Reduced muscle weakness

The study included a planned schedule to slowly reduce steroid doses. 87.4% of patients on UPLIZNA and 84.6% of patients on placebo reduced their steroid dose to ≤5 mg/day.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about UPLIZNA? (cont'd)

Infections. Infections can happen during treatment with UPLIZNA. Tell your healthcare provider right away if you have an infection or get any of these symptoms:

- painful and frequent urination
- nasal congestion, runny nose, sore throat, fever, chills, cough, body aches

- UPLIZNA taken before or after other medicines that weaken the immune system may increase your risk of getting infections.
- **Hepatitis B virus (HBV) reactivation.** Before starting treatment with UPLIZNA, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with UPLIZNA. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems, including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving UPLIZNA.

UPLIZNA showed **improvement in daily activities and reduction in muscle weakness**

UPLIZNA®
inebilizumab-cdon

Study Results

Based on a 26-week study, UPLIZNA delivered:*,†

2x

improvement in daily activities

Patients taking UPLIZNA had a 4.2 point improvement in MG-ADL score vs a 2.2 point improvement for patients on placebo.‡

2x

reduction in muscle weakness

Patients taking UPLIZNA had a 4.8 point improvement in muscle weakness according to the QMG scale vs a 2.3 point improvement on placebo.‡

Scan to see more data for UPLIZNA in both anti-AChR and anti-MuSK antibody positive patients

*Myasthenia Gravis Activities of Daily Living (MG-ADL) scale measures daily functions of 8 signs or symptoms that are typically affected in gMG.

†Measured by the Quantitative Myasthenia Gravis (QMG) score, a 13-item categorical grading system that assesses muscle weakness.

‡Placebo is a substance that has no therapeutic effect and is often used as a control in testing drugs.

UPLIZNA has an **established safety profile**

The most common side effects of UPLIZNA in the clinical study for gMG were:

- Headache (15%)
- Infusion-related reaction (10%)



UPLIZNA is also approved in
2 other rare diseases

UPLIZNA is a prescription medicine used to treat adults with:

- Neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive
- Immunoglobulin G4-related disease (IgG4-RD)

It is not known if UPLIZNA is safe or effective in children.

IMPORTANT SAFETY INFORMATION (cont'd)

What is the most important information I should know about UPLIZNA? (cont'd)

- **Progressive Multifocal Leukoencephalopathy (PML).** PML may happen with UPLIZNA. PML is a rare brain infection that leads to death or severe disability. Symptoms of PML may get worse over days to weeks. Call your healthcare provider right away if you get any of these symptoms:
  - weakness on one side of the body
  - loss of coordination in your arms and legs
  - changes in your vision
  - changes in thinking or memory
  - confusion
  - changes in your personality
- **Tuberculosis (TB).** TB is caused by an infection in the lungs. Before starting treatment with UPLIZNA, your healthcare provider will check to see if you are at risk for getting TB or have ever had TB.
- **Vaccinations.** Certain vaccines, called "live" or "live attenuated" vaccines, are not recommended in people receiving UPLIZNA. Talk to your healthcare provider before receiving any vaccinations. If you have a baby and you were receiving UPLIZNA during pregnancy, it is important to tell your baby's healthcare provider about your UPLIZNA use so they can decide when your baby should receive any vaccine.

Before receiving UPLIZNA, tell your healthcare provider about all of your medical conditions, including if you:

- have or think you have an infection.
- have ever taken, currently take, or plan to take medicines that affect your immune system, or other treatments for NMOSD, IgG4-RD, or gMG. These medicines may increase your risk of getting an infection.

Twice-yearly dosing to fit your lifestyle

UPLIZNA®
inebilizumab-cdon

UPLIZNA is just 2 doses per year (after 2 startup doses), **offering 6 months of time between treatments**

INITIAL DOSING
on Day 1 and Day 15

MAINTENANCE DOSE
every 6 months



Each infusion takes about **90 minutes**

It's important to find a gMG medication that works for you. No matter where you are in your treatment journey, talk with your doctor about treatment options.

A conversation with your doctor could make all the difference

Prepare

Before your next doctor visit:

1. **Identify your treatment goals** and any questions you may have
2. **Keep track of your symptoms**
3. **Come prepared** to discuss what you're experiencing to help make more informed treatment decisions

Scan for a gMG doctor discussion guide

Consider

Factors to keep in mind when discussing treatment options:

Improvement in symptoms

Possible side effects

How the treatment works in your body

Administration and dosing schedule

IMPORTANT SAFETY INFORMATION (cont'd)

Before receiving UPLIZNA, tell your healthcare provider about all of your medical conditions, including if you (cont'd):

- have or have ever had hepatitis B or are a carrier of the hepatitis B virus.
- have or have ever had tuberculosis.
- have had a recent vaccination or are scheduled to receive any vaccinations. You should receive any required vaccines at least 4 weeks before you start treatment with UPLIZNA.
- are pregnant or plan to become pregnant. It is not known if UPLIZNA will harm your unborn baby. Females should use birth control (contraception) during treatment with UPLIZNA and for 6 months after your last infusion of UPLIZNA.
- are breastfeeding or plan to breastfeed. It is not known if UPLIZNA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive UPLIZNA.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see UPLIZNA full Prescribing Information, including Medication Guide.

Personalized support is available through Amgen By Your Side

UPLIZNA® inebilizumab-cdon

Amgen By Your Side is a patient support program designed specifically for patients like you, patients prescribed UPLIZNA. Once your enrollment in Amgen By Your Side is complete, you will be paired with a dedicated Patient Access Liaison (PAL).

Your PAL will serve as your partner, providing nonmedical, personalized support to help you navigate your unique experience, including information on:

Insurance

Financial support options

Upcoming appointments

Other patient support services

How to enroll

Once you and your doctor decide that UPLIZNA is right for you, you can enroll in Amgen By Your Side. There is no cost to enroll, and you can enroll in one of two ways:

Option 1

Sign up through your doctor's office. They can start the enrollment process on **AmgenByYourSide.com** and submit your application on your behalf. Your consent will be required to complete enrollment.

Option 2

If you have a prescription for UPLIZNA, call **1-833-842-8477** to get connected. A PAL will help you explore enrollment options.

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of UPLIZNA?

UPLIZNA may cause serious side effects, including:

- **low blood cell counts.** UPLIZNA may cause a decrease in some types of blood cells. Your healthcare provider will do blood tests to check your blood cell counts.

For adult patients with generalized myasthenia gravis (gMG) who are anti-AChR or anti-MuSK antibody positive

UPLIZNA® inebilizumab-cdon

FDA-approved UPLIZNA works differently by targeting CD19 B cells, a key source of gMG*

2x improvement in daily activities

In a 26-week study, patients taking UPLIZNA had a 4.2 point improvement in MG-ADL score vs a 2.2 point improvement for patients on placebo.†,‡

Just 2 infusions per year

Twice-yearly dosing begins after 2 startup infusions, given 2 weeks apart.

Safety profile backed by results from the largest study of adult patients with anti-AChR and anti-MuSK antibody positive gMG

The most common side effects were headache and infusion-related reaction.

*While the way UPLIZNA works in gMG is unknown, it is thought to target and reduce B cells.

†Myasthenia Gravis Activities of Daily Living (MG-ADL) scale measures daily functions of 8 signs or symptoms that are typically affected in gMG.

‡Placebo is a substance that has no therapeutic effect and is often used as a control in testing drugs.

IMPORTANT SAFETY INFORMATION (cont'd)

UPLIZNA may cause serious side effects, including (cont'd):

The most common side effects include: urinary tract infection and joint pain in patients with NMOSD; urinary tract infection and low white blood cell count in patients with IgG4-RD; headache and infusion-related reaction in patients with gMG. These are not all the possible side effects of UPLIZNA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see UPLIZNA full Prescribing Information, including Medication Guide.

© 2025 Amgen Inc. USA-335-80969 12/25

AMGEN